Moderna-Merck Phase 3 melanoma vaccine regimen cuts recurrence/death risk 42%
Merck and Moderna reported detailed Phase 3 INTerpath-001 data for individualized mRNA vaccine intismeran autogene plus Keytruda versus Keytruda alone in more than 1,100 patients with melanoma. The combination reduced the reported risk of melanoma recurrence or death by 42% and disease spread by 38%, with no new safety signals; detailed results were scheduled for presentation at the European Society for Medical Oncology meeting.
This is a valid forward-looking clinical development because Reuters and Merck reported new quantitative Phase 3 efficacy and safety information for the INTerpath-001 melanoma program: intismeran plus Keytruda reduced the reported risks of recurrence or death and disease spread versus Keytruda alone, with no new safety signals. The result can change regulatory-filing, approval, and commercialization expectations for Moderna and Merck, although no approval or filing is reported. It is a distinct milestone from the August topline endpoint announcement because the effect sizes and safety update are newly disclosed, but it remains part of the existing Merck–Moderna Phase 3 melanoma program. Importance is high but below a wholly new trial success because the positive endpoints were previously announced; surprise is moderate because investors were already expecting a strong readout and analysts had been looking for a recurrence-risk reduction of at least 40%. Confidence is high because the core facts are supported by a Reuters report and two near-contemporaneous Merck statements. The timestamp reflects the supplied timing of the new disclosure, while the formal ESMO presentation was still scheduled, so the occurrence status is marked as announced. Only MRNA and MRK are approved because the possible effects on other companies are indirect and conditional.
An mRNA cancer vaccine developed by Moderna NASDAQ:MRNA and Merck NYSE:MRK in combination with a widely used immunotherapy cut the risk of death or recurrence of melanoma by 42% and disease spread by 38%, according to data from a large trial, potentially paving the way for a new era of personalized treatment.
MERCK SAYS INTISMERAN PLUS KEYTRUDA SIGNIFICANTLY REDUCED THE RISK OF RECURRENCE OR DEATH BY 42% COMPARED TO KEYTRUDA ALONE, WITH A 58% REDUCTION IN ANOTHER MEASURE, AND THAT THE SAFETY PROFILE WAS GENERALLY CONSISTENT WITH PREVIOUSLY REPORTED STUDIES OF THE COMBINATION
MERCK SAYS THAT IN THE PHASE 3 INTERPATH-001 TRIAL NO NEW SAFETY SIGNALS WERE OBSERVED
INTerpath-001 showed improved RFS and DMFS with intismeran plus pembrolizumab versus pembrolizumab alone in resected stage IIB–IV melanoma. The combination had similar rates of serious adverse events, while overall-survival follow-up continues.